By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Proteome Sciences today announced a contract with Japanese drug firm Eisai to provide biomarker services for Alzheimer's disease.

Under the terms of the deal, Proteome Sciences, based in Surrey, UK, will measure candidate biomarkers for AD using its AD-TMT-SRM assay set on human samples, it said in a statement.

Financial and other terms of the deal were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.